Form 4: Immix Biopharma Director Jason Hsu Buys Additional Shares

Director Jason Hsu of Immix Biopharma, Inc. [IMMX] recently purchased shares of common stock in two transactions on August 21 and August 22, 2024.

Summary

• On August 21, 2024, Jason Hsu, a director of Immix Biopharma, purchased 15,000 shares of common stock at a weighted average price of $2.226 per share.
• Following this transaction, Mr. Hsu directly owns 837,200 shares.
• On August 22, 2024, Mr. Hsu purchased an additional 8,100 shares at a weighted average price of $2.251 per share, increasing his direct holdings to 845,300 shares.
• Mr. Hsu also indirectly owns 3,915,913 shares through VERITAS LIBERABIT VOS, LLC and 50,000 shares through Signature Collection Properties, LLC, but disclaims beneficial ownership except to the extent of his pecuniary interest.
• The transactions were executed in multiple trades at varying prices within specified ranges.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The director's purchase suggests confidence, but it's a relatively small transaction in the context of overall holdings.

Positives

• The director's purchase of shares may signal confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders of a company (officers, directors, or those holding more than 10% of the company's shares) buy or sell the company's securities. These filings provide transparency into insider transactions and can be used by investors to gauge sentiment about the company's prospects.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder sentiment.

Key Dates